Literature DB >> 15212824

Early complement activation increases in the brain in some aged normal subjects.

David A Loeffler1, Dianne M Camp, Michael B Schonberger, Daniel J Singer, Peter A LeWitt.   

Abstract

Complement activation is increased in Alzheimer's disease (AD) and may contribute to the development and progression of this disorder. To compare early complement activation between normal and AD brain specimens, C4d and iC3b concentrations were measured in hippocampus, entorhinal cortex, temporal cortex, parietal cortex, and cerebellum from aged normal and AD subjects n=10-14 for both), and in hippocampus and entorhinal cortex from younger normal subjects (n=5-6). C4d and iC3b levels increased 2.3- to 4.6-fold in AD versus aged normal specimens (all P <0.05), with lowest concentrations of these activation proteins generally in cerebellum. No significant differences were present between aged and younger normal C4d and iC3b levels in hippocampus or entorhinal cortex. However, the concentrations of these proteins were markedly increased in several aged normal specimens. Normal subject age was moderately associated with both C4d (r=0.49) and iC3b (r=0.53) concentrations in the hippocampus. Increased brain complement activation in some elderly individuals may promote the subsequent development of AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15212824     DOI: 10.1016/j.neurobiolaging.2003.11.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  6 in total

Review 1.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

2.  Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma.

Authors:  Luis Villela; Mauricio García; Rocío Caballero; José R Borbolla-Escoboza; Javier Bolaños-Meade
Journal:  Anticancer Drugs       Date:  2008-10       Impact factor: 2.248

3.  Genetic control of the alternative pathway of complement in humans and age-related macular degeneration.

Authors:  Laura A Hecker; Albert O Edwards; Euijung Ryu; Nirubol Tosakulwong; Keith H Baratz; William L Brown; Peter Charbel Issa; Hendrik P Scholl; Beatrix Pollok-Kopp; Katharina E Schmid-Kubista; Kent R Bailey; Martin Oppermann
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

4.  Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Authors:  Richard J Perrin; Rebecca Craig-Schapiro; James P Malone; Aarti R Shah; Petra Gilmore; Alan E Davis; Catherine M Roe; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Jeffrey A Kaye; John C Morris; David M Holtzman; R Reid Townsend; Anne M Fagan
Journal:  PLoS One       Date:  2011-01-12       Impact factor: 3.240

5.  Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.

Authors:  Markus Britschgi; Yoshiko Takeda-Uchimura; Edward Rockenstein; Hudson Johns; Eliezer Masliah; Tony Wyss-Coray
Journal:  J Neuroinflammation       Date:  2012-09-18       Impact factor: 8.322

6.  Using animal models to determine the significance of complement activation in Alzheimer's disease.

Authors:  David A Loeffler
Journal:  J Neuroinflammation       Date:  2004-10-12       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.